NasdaqCM - Nasdaq Real Time Price USD

Organogenesis Holdings Inc. (ORGO)

5.51
+0.33
+(6.27%)
As of 2:52:39 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
482,043
482,043
433,140
450,893
467,359
Cost of Revenue
115,741
115,741
106,481
105,019
114,199
Gross Profit
366,302
366,302
326,659
345,874
353,160
Operating Expense
344,784
344,784
314,134
323,570
280,942
Operating Income
21,518
21,518
12,525
22,304
72,218
Net Non Operating Interest Income Expense
-1,544
-1,544
-2,190
-2,009
-7,236
Other Income Expense
-22,781
-22,781
57
-13
-1,896
Pretax Income
-2,807
-2,807
10,392
20,282
63,086
Tax Provision
-3,668
-3,668
5,447
4,750
-31,116
Net Income Common Stockholders
-937
-937
4,945
15,532
94,202
Diluted NI Available to Com Stockholders
-937
-937
4,945
15,532
94,202
Basic EPS
-0.01
-0.01
0.04
0.12
0.74
Diluted EPS
-0.01
-0.01
0.04
0.12
0.71
Basic Average Shares
131,673.28
131,673.28
131,231.32
130,070.23
128,331.02
Diluted Average Shares
131,673.28
131,673.28
132,746.73
132,383.15
133,662.66
Total Operating Income as Reported
-1,283
-1,283
12,525
22,304
72,218
Total Expenses
460,525
460,525
420,615
428,589
395,141
Net Income from Continuing & Discontinued Operation
861
861
4,945
15,532
94,202
Normalized Income
18,873.79
18,873.79
4,945
15,532
95,576.59
Interest Expense
1,544
1,544
2,190
2,009
7,236
Net Interest Income
-1,544
-1,544
-2,190
-2,009
-7,236
EBIT
-1,263
-1,263
12,582
22,291
70,322
EBITDA
15,763
15,763
27,948
33,019
86,998
Reconciled Cost of Revenue
115,741
115,741
106,481
105,019
114,199
Reconciled Depreciation
17,026
17,026
15,366
10,728
16,676
Net Income from Continuing Operation Net Minority Interest
861
861
4,945
15,532
94,202
Total Unusual Items Excluding Goodwill
-22,801
-22,801
0
0
-1,883
Total Unusual Items
-22,801
-22,801
0
0
-1,883
Normalized EBITDA
38,564
38,564
27,948
33,019
88,881
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-4,788.21
-4,788.21
0
0
-508.41
12/31/2021 - 1/5/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PCRX Pacira BioSciences, Inc.
24.99
-0.75%
 
ANIP ANI Pharmaceuticals, Inc.
71.56
+1.04%
 
AMRX Amneal Pharmaceuticals, Inc.
7.52
+4.09%
 
CPIX Cumberland Pharmaceuticals Inc.
4.4800
+1.35%
 
KNSA Kiniksa Pharmaceuticals International, plc
26.82
+0.19%
 
SXTC China SXT Pharmaceuticals, Inc.
2.0200
+6.38%
 
ESPR Esperion Therapeutics, Inc.
0.8940
+2.65%
 
GPFT Grapefruit USA, Inc.
0.0008
-11.11%
 
PRGO Perrigo Company plc
26.85
+1.67%
 
EBS Emergent BioSolutions Inc.
6.60
+39.31%